Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Asymmetrical atrophy of thalamic subnuclei in Alzheimer's disease and amyloid-positive mild cognitive impairment is associated with key clinical features.

Low A, Mak E, Malpetti M, Chouliaras L, Nicastro N, Su L, Holland N, Rittman T, Rodríguez PV, Passamonti L, Bevan-Jones WR, Jones PS, Rowe JB, O'Brien JT.

Alzheimers Dement (Amst). 2019 Oct 1;11:690-699. doi: 10.1016/j.dadm.2019.08.001. eCollection 2019 Dec.

2.
3.

Test Your Memory (TYM test): diagnostic evaluation of patients with non-Alzheimer dementias.

Brown J, Wiggins J, Lansdall CJ, Dawson K, Rittman T, Rowe JB.

J Neurol. 2019 Oct;266(10):2546-2553. doi: 10.1007/s00415-019-09447-1. Epub 2019 Jul 2.

4.

In Vivo Assay of Cortical Microcircuitry in Frontotemporal Dementia: A Platform for Experimental Medicine Studies.

Shaw AD, Hughes LE, Moran R, Coyle-Gilchrist I, Rittman T, Rowe JB.

Cereb Cortex. 2019 Jun 19. pii: bhz024. doi: 10.1093/cercor/bhz024. [Epub ahead of print]

PMID:
31216360
5.

Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia.

Rittman T, Borchert R, Jones S, van Swieten J, Borroni B, Galimberti D, Masellis M, Tartaglia MC, Graff C, Tagliavini F, Frisoni GB, Laforce R Jr, Finger E, Mendonça A, Sorbi S, Rohrer JD, Rowe JB; Genetic Frontotemporal Dementia Initiative (GENFI).

Neurobiol Aging. 2019 May;77:169-177. doi: 10.1016/j.neurobiolaging.2018.12.009. Epub 2019 Jan 4.

6.

In vivo coupling of tau pathology and cortical thinning in Alzheimer's disease.

Mak E, Bethlehem RAI, Romero-Garcia R, Cervenka S, Rittman T, Gabel S, Surendranathan A, Bevan-Jones RW, Passamonti L, Vázquez Rodríguez P, Su L, Arnold R, Williams GB, Hong YT, Fryer TD, Aigbirhio FI, Rowe JB, O'Brien JT.

Alzheimers Dement (Amst). 2018 Sep 17;10:678-687. doi: 10.1016/j.dadm.2018.08.005. eCollection 2018.

7.

Reply: Brain oscillations, inhibition and social inappropriateness in frontotemporal degeneration.

Hughes LE, Rittman T, Robbins TW, Rowe JB.

Brain. 2018 Oct 1;141(10):e74. doi: 10.1093/brain/awy235. No abstract available.

PMID:
30212860
8.

Neurophysiological signatures of Alzheimer's disease and frontotemporal lobar degeneration: pathology versus phenotype.

Sami S, Williams N, Hughes LE, Cope TE, Rittman T, Coyle-Gilchrist ITS, Henson RN, Rowe JB.

Brain. 2018 Aug 1;141(8):2500-2510. doi: 10.1093/brain/awy180.

9.

Reorganization of cortical oscillatory dynamics underlying disinhibition in frontotemporal dementia.

Hughes LE, Rittman T, Robbins TW, Rowe JB.

Brain. 2018 Aug 1;141(8):2486-2499. doi: 10.1093/brain/awy176.

10.

Tau burden and the functional connectome in Alzheimer's disease and progressive supranuclear palsy.

Cope TE, Rittman T, Borchert RJ, Jones PS, Vatansever D, Allinson K, Passamonti L, Vazquez Rodriguez P, Bevan-Jones WR, O'Brien JT, Rowe JB.

Brain. 2018 Feb 1;141(2):550-567. doi: 10.1093/brain/awx347.

11.

Atomoxetine effects on attentional bias to drug-related cues in cocaine dependent individuals.

Passamonti L, Luijten M, Ziauddeen H, Coyle-Gilchrist ITS, Rittman T, Brain SAE, Regenthal R, Franken IHA, Sahakian BJ, Bullmore ET, Robbins TW, Ersche KD.

Psychopharmacology (Berl). 2017 Aug;234(15):2289-2297. doi: 10.1007/s00213-017-4643-4. Epub 2017 May 27.

12.

Managing cognition in progressive supranuclear palsy.

Rittman T, Coyle-Gilchrist IT, Rowe JB.

Neurodegener Dis Manag. 2016 Dec;6(6):499-508. Epub 2016 Nov 23. Review.

13.

Regional expression of the MAPT gene is associated with loss of hubs in brain networks and cognitive impairment in Parkinson disease and progressive supranuclear palsy.

Rittman T, Rubinov M, Vértes PE, Patel AX, Ginestet CE, Ghosh BCP, Barker RA, Spillantini MG, Bullmore ET, Rowe JB.

Neurobiol Aging. 2016 Dec;48:153-160. doi: 10.1016/j.neurobiolaging.2016.09.001. Epub 2016 Sep 9.

14.

Gene transcription profiles associated with inter-modular hubs and connection distance in human functional magnetic resonance imaging networks.

Vértes PE, Rittman T, Whitaker KJ, Romero-Garcia R, Váša F, Kitzbichler MG, Wagstyl K, Fonagy P, Dolan RJ, Jones PB, Goodyer IM; NSPN Consortium, Bullmore ET.

Philos Trans R Soc Lond B Biol Sci. 2016 Oct 5;371(1705). pii: 20150362. doi: 10.1098/rstb.2015.0362.

15.

Adolescence is associated with genomically patterned consolidation of the hubs of the human brain connectome.

Whitaker KJ, Vértes PE, Romero-Garcia R, Váša F, Moutoussis M, Prabhu G, Weiskopf N, Callaghan MF, Wagstyl K, Rittman T, Tait R, Ooi C, Suckling J, Inkster B, Fonagy P, Dolan RJ, Jones PB, Goodyer IM; NSPN Consortium, Bullmore ET.

Proc Natl Acad Sci U S A. 2016 Aug 9;113(32):9105-10. doi: 10.1073/pnas.1601745113. Epub 2016 Jul 25.

16.

Atomoxetine restores the response inhibition network in Parkinson's disease.

Rae CL, Nombela C, Rodríguez PV, Ye Z, Hughes LE, Jones PS, Ham T, Rittman T, Coyle-Gilchrist I, Regenthal R, Sahakian BJ, Barker RA, Robbins TW, Rowe JB.

Brain. 2016 Aug;139(Pt 8):2235-48. doi: 10.1093/brain/aww138. Epub 2016 Jun 24.

17.

Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's Disease.

Borchert RJ, Rittman T, Passamonti L, Ye Z, Sami S, Jones SP, Nombela C, Rodríguez PV, Vatansever D, Rae CL, Hughes LE, Robbins TW, Rowe JB.

Neuropsychopharmacology. 2016 Jul;41(8):2188. doi: 10.1038/npp.2016.46. No abstract available.

18.

Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's Disease.

Borchert RJ, Rittman T, Passamonti L, Ye Z, Sami S, Jones SP, Nombela C, Vázquez Rodríguez P, Vatansever D, Rae CL, Hughes LE, Robbins TW, Rowe JB.

Neuropsychopharmacology. 2016 Jul;41(8):2171-7. doi: 10.1038/npp.2016.18. Epub 2016 Feb 3. Erratum in: Neuropsychopharmacology. 2016 Jul;41(8):2188.

19.

Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures.

Ye Z, Rae CL, Nombela C, Ham T, Rittman T, Jones PS, Rodríguez PV, Coyle-Gilchrist I, Regenthal R, Altena E, Housden CR, Maxwell H, Sahakian BJ, Barker RA, Robbins TW, Rowe JB.

Hum Brain Mapp. 2016 Mar;37(3):1026-37. doi: 10.1002/hbm.23087. Epub 2016 Jan 12.

20.

Different decision deficits impair response inhibition in progressive supranuclear palsy and Parkinson's disease.

Zhang J, Rittman T, Nombela C, Fois A, Coyle-Gilchrist I, Barker RA, Hughes LE, Rowe JB.

Brain. 2016 Jan;139(Pt 1):161-73. doi: 10.1093/brain/awv331. Epub 2015 Nov 18.

21.

Improving response inhibition systems in frontotemporal dementia with citalopram.

Hughes LE, Rittman T, Regenthal R, Robbins TW, Rowe JB.

Brain. 2015 Jul;138(Pt 7):1961-75. doi: 10.1093/brain/awv133. Epub 2015 May 21.

22.

Improving response inhibition in Parkinson's disease with atomoxetine.

Ye Z, Altena E, Nombela C, Housden CR, Maxwell H, Rittman T, Huddleston C, Rae CL, Regenthal R, Sahakian BJ, Barker RA, Robbins TW, Rowe JB.

Biol Psychiatry. 2015 Apr 15;77(8):740-8. doi: 10.1016/j.biopsych.2014.01.024. Epub 2014 Feb 7.

23.

Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease.

Ye Z, Altena E, Nombela C, Housden CR, Maxwell H, Rittman T, Huddleston C, Rae CL, Regenthal R, Sahakian BJ, Barker RA, Robbins TW, Rowe JB.

Brain. 2014 Apr;137(Pt 4):1145-55. doi: 10.1093/brain/awu032. Epub 2014 Feb 27.

24.

Validation of the new consensus criteria for the diagnosis of corticobasal degeneration.

Alexander SK, Rittman T, Xuereb JH, Bak TH, Hodges JR, Rowe JB.

J Neurol Neurosurg Psychiatry. 2014 Aug;85(8):925-9. doi: 10.1136/jnnp-2013-307035. Epub 2014 Feb 12.

25.

Multiple modes of impulsivity in Parkinson's disease.

Nombela C, Rittman T, Robbins TW, Rowe JB.

PLoS One. 2014 Jan 21;9(1):e85747. doi: 10.1371/journal.pone.0085747. eCollection 2014.

26.

The medial frontal-prefrontal network for altered awareness and control of action in corticobasal syndrome.

Wolpe N, Moore JW, Rae CL, Rittman T, Altena E, Haggard P, Rowe JB.

Brain. 2014 Jan;137(Pt 1):208-20. doi: 10.1093/brain/awt302. Epub 2013 Nov 29.

27.

The Addenbrooke's Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders.

Rittman T, Ghosh BC, McColgan P, Breen DP, Evans J, Williams-Gray CH, Barker RA, Rowe JB.

J Neurol Neurosurg Psychiatry. 2013 May;84(5):544-51. doi: 10.1136/jnnp-2012-303618. Epub 2013 Jan 8.

28.

Transcriptional data: a new gateway to drug repositioning?

Iorio F, Rittman T, Ge H, Menden M, Saez-Rodriguez J.

Drug Discov Today. 2013 Apr;18(7-8):350-7. doi: 10.1016/j.drudis.2012.07.014. Epub 2012 Aug 7.

29.

Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in healthy volunteers.

Müller U, Rowe JB, Rittman T, Lewis C, Robbins TW, Sahakian BJ.

Neuropharmacology. 2013 Jan;64:490-5. doi: 10.1016/j.neuropharm.2012.07.009. Epub 2012 Jul 20.

30.

Is referral to the neuro-oncology MDT safe?

Rittman T, Corns R, Kumar A, Bhangoo R, Ashkan K.

Br J Neurosurg. 2012 Jun;26(3):321-4. doi: 10.3109/02688697.2012.657267. Epub 2012 Feb 9.

PMID:
22320443
31.

T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease.

Schwarz ST, Rittman T, Gontu V, Morgan PS, Bajaj N, Auer DP.

Mov Disord. 2011 Aug 1;26(9):1633-8. doi: 10.1002/mds.23722. Epub 2011 Apr 12. Erratum in: Mov Disord. 2012 Feb;27(2):335.

PMID:
21491489
32.

Anatomic-manometric correlation of the upper esophageal sphincter: a concurrent US and manometry study.

Hernandez LV, Dua KS, Surapaneni SN, Rittman T, Shaker R.

Gastrointest Endosc. 2010 Sep;72(3):587-92. doi: 10.1016/j.gie.2010.04.029. Epub 2010 Jun 25.

33.

Nutritional factors associated with survival following enteral tube feeding in patients with motor neurone disease.

Rio A, Ellis C, Shaw C, Willey E, Ampong MA, Wijesekera L, Rittman T, Nigel Leigh P, Sidhu PS, Al-Chalabi A.

J Hum Nutr Diet. 2010 Aug;23(4):408-15. doi: 10.1111/j.1365-277X.2010.01057.x. Epub 2010 May 13.

PMID:
20487174
34.

Human papillomavirus infection in women who develop high-grade cervical intraepithelial neoplasia or cervical cancer: a case-control study in the UK.

Grainge MJ, Seth R, Coupland C, Guo L, Rittman T, Vryenhoef P, Johnson J, Jenkins D, Neal KR.

Br J Cancer. 2005 May 9;92(9):1794-9.

Supplemental Content

Loading ...
Support Center